Pharmacokinetics of SPR206 in Plasma, Pulmonary Epithelial Lining Fluid, and Alveolar Macrophages following Intravenous Administration to Healthy Adult Subjects

SPR206 is a next-generation polymyxin being developed for the treatment of multidrug-resistant (MDR) Gram-negative infections. This Phase 1 bronchoalveolar lavage (BAL) study was conducted to evaluate SPR206’s safety and pharmacokinetics in plasma, pulmonary epithelial lining fluid (ELF), and alveol...

Descripción completa

Detalles Bibliográficos
Autores principales: Rodvold, Keith A., Bader, Justin, Bruss, Jon B., Hamed, Kamal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353446/
https://www.ncbi.nlm.nih.gov/pubmed/37338378
http://dx.doi.org/10.1128/aac.00426-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10353446/
https://www.ncbi.nlm.nih.gov/pubmed/37338378
http://dx.doi.org/10.1128/aac.00426-23

Ejemplares similares